Additionally, recombinant human Flt3L has been administered to mice in combination with immunostimulatory DNA and tumor antigens to raise efficient antitumor immune responses that rely on CD8+ T cells and NK cells [81]. This evidence concerns the gene CD8A and neoplasm.